TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04359563

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Intervention
Description: The MBI consists of four 2h online group sessions spread over eight weeks. In between sessions, online support will be offered to assist participants in their practice. Each session consists of guided mindfulness exercises (e.g., focus on the breath, body scan, breathing space, mindful yoga, insight meditation, walk meditation), sharing of experiences of these exercises, reflections in small groups, psycho-education (e.g., stress, depression, self-care), and review of home practices. An overview of core elements is given in Van der Gucht et al. (2017b).~The MBI is supported by homework assignments and audio material. Groups will include 5 participants, yielding 6 groups in total. The MBI will be delivered by highly qualified certified trainers with more than 10 years of experience in mindfulness meditation and extensive experience working with adolescents. Trainers will attend inter- and supervision moments on a regular basis to check treatment fidelity and trainer adherence.
Study: NCT02201979

Intervention type: PROCEDURE
Intervention: Vertical breast lift with implants
Study: NCT03556891

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: eCoin Tibial Nerve Stimulation
Description: Subcutaneous stimulation of the tibial nerve using the eCoin device.
Study: NCT02434107

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Clinical Monitoring (Palpation and node ultrasound)
Study: NCT02916758

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Let's Go Community Mobility Program
Description: Four week multi-modal education and experiential program to improve community mobilty
Study: NCT02014766

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interscalene block
Description: Ultrasound-guided interscalene block is performed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supraclavicular block
Description: Ultrasound-guided supraclavicular block is performed
Study: NCT02343211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunoglobulin
Study: NCT02448446

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab 0.3mg
Description: intravitreally administered

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab 0.3mg
Description: intravitreally administered
Study: NCT04136613

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Copper Intra uterine contarceptive device ( Cu-T 380A)
Description: Insertion of the Cu-T 380A during cesarean delivery immediately after placental removal.
Study: NCT03638661

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vegetable (canola, flaxseed) derived n-3 fatty acid
Description: vegetable (canola, flaxseed) derived n-3 fatty acid was used for fat source.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: soybean oil
Description: soybean oil used formula
Study: NCT03348111

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Air-polishing device
Description: Air abrasion using the Air-Flow Master Piezon® with erythritol and Chlorhexidine powders on implants presenting clinical and radiographic signs of mucositis and peri-implantitis along with renewal of local oral hygiene instructions in order to reduce the inflammation locally
Study: NCT02700100

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bioabsorbable Pulmonary Valved Conduit (PV-001)
Description: The Bioabsorbable Pulmonary Valved (PV) Conduit (PV-001) is a polymer-based medical device, with a total length of 8 cm with inner diameters of 16 or 18 mm. The valve itself is formed by three leaflets, incorporated within the conduit wall.~The PV conduit is used for correction or reconstruction of the Right Ventricular Outflow Tract (RVOT) in patients with any of the following congenital heart malformations:~* Tetralogy of Fallot~* Truncus Arteriosus~* Pulmonary Atresia~* Transposition of Great Arteries with Ventricular Septal Defect (VSD)~* Pulmonary Stenosis in combination with other defects in congenital heart defect (CHD) syndromes~The PV conduit can also be used for replacement of previously implanted, but dysfunctional, pulmonary homografts or valved conduits.
Study: NCT00864422

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Skilled motor training
Description: This involves training subjects to independently and cognitively activate the deep abdominal muscles, transversus abdominis, with minimal or no activity in other trunk muscles. The contraction is held for 10 seconds and subjects complete three blocks of ten contractions, twice per day for two weeks. This training protocol is commonly used clinically for people with chronic back pain.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Walking exercise
Description: The control intervention involves walking exercises for ten minutes, twice per day. Subjects are advised to walk at their own pace with no instructions on activation of specific trunk muscles. The exercise is performed over two weeks.
Study: NCT01800006

Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: Patients with non-valvular atrial fibrillation who are prescribed Rivaroxaban under routine treatment conditions to prevent stroke or non-central nervous system systemic embolism. Decision regarding dose and duration of treatment made at the discretion of the attending investigator.
Study: NCT02986893

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Participants will be assigned to follow a specific diet for 6 months. This will involve meetings with the study nutritionist at least monthly as well as regular assessments related to adherence and effects.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non-dietary Intervention Arm
Description: Participants will be requested to follow their usual diet and attend monthly meetings at the MS center to discuss various topics with a focus on wellness in MS for 6 months.
Study: NCT02016521

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cooling Fabric
Description: Garment made of 100% nylon and consisting of long sleeved shirt and full trouser.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Garment
Description: Garment made of 100% polyester consisting of long sleeved shirt and full trouser
Study: NCT03021291

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gelesis100 (2.25 g)
Description: Three capsules of Gelesis100, each containing a 750 mg mixture of two food-grade materials: carboxymethylcellulose that is cross-linked with citric acid.
Study: NCT02124707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: 400mg/m2 IV (in the vein) on day 1 of week 1 and 250mg/m2 IV (in the vein) on day 1 of weeks 2-6. Patients with stable disease may continue on maintenance therapy at the 250mg/m2 dose until disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 135mg/m2 IV (in the vein) on day 1 of each 1 week for 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC2, IV (in the vein) on day 1 of each 1 week for 6 weeks.
Study: NCT01268423

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous tracheostomy
Description: Percutaneous tracheostomy within the first 4 days of mechanical ventilation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged translaryngeal intubation
Description: Prolonged endotracheal intubation, and reevaluation at day 10 to establish the requirement of percutaneous tracheostomy. If clinical condition determines that the patient needs a percutaneous tracheostomy, this will be performed between days 11 and 14.
Study: NCT01393171

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Polypropylene mesh (Polyform by Boston Scientific)
Description: Site-specific cystocele repair with polypropylene mesh augmentation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Porcine Dermis (Pelvicol by CRBard)
Description: Site-specific cystocele repair with porcine dermis augmentation

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Anterior Colporrhaphy
Description: Anterior vaginal prolapse repair with suture.
Study: NCT01593501

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D3
Description: pharmaceutical grade D3
Study: NCT01657981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM150
Description: 14C-labeled YM150, oral solution
Study: NCT00867607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRX-6
Description: b.i.d treatment for 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRX-6
Description: b.i.d treatment for 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRX-6
Description: b.i.d treatment for 21 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Steroid
Description: b.i.d. 21 days
Study: NCT03519984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV
Study: NCT01593501

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: vitamin D3
Description: pharmaceutical grade D3
Study: NCT02815176

Intervention type: OTHER
Intervention: Blood sampling
Description: Sampling the blood including DNA to investigate the thrombotic profile

Intervention type: OTHER
Intervention: Blood sampling
Description: Sampling the blood including DNA to investigate the thrombotic profile
Study: NCT02947984

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Standard Treatment
Description: 55.8 CGE in 31 treatments of 1.8 CGE given once a day, for five days each week. Treatment based upon a treatment planning CT.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Higher Dose
Description: 55.8 CGE in 31 treatments of 1.8 CGE given once a day, for five days each week. Treatment based upon a treatment planning CT.
Study: NCT03519984

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01128478

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Enteral tube feeding
Description: Nasogastric tube feeding started within 24 h of hospital admission
Study: NCT02550145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exendin (9-39)
Description: IV infusion of Exendin (9-39) during standardized oral glucose tolerance test (OGTT).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV infusion of Placebo (normal saline) during standardized oral glucose tolerance test (OGTT)
Study: NCT04924348

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Experimental: WALANT procedure
Description: The WALANT technique, performed under ultrasound, includes two punctures.~* The first is a puncture through a medial approach above the wrist and includes two injections. A first subcutaneous injection reproducing a bar above the wrist flexion line, and a second injection above the median nerve. The volumes injected vary from 8 to 10 milliliters (ml).~* The second puncture is performed at the base of the palmar surface of the hand and consists of a 10 ml subcutaneous injection of the local anesthetic in order to take advantage of the vasoconstrictive effects of adrenaline, thus allowing the surgical procedure to be performed without a pneumatic tourniquet.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Axial ALR
Description: The anesthetic protocol in the axillary block consists of performing a puncture, using a needle (50 mm 22G with a short bevel), under the armpit at the level of the axillary hollow after skin disinfection. This puncture, performed under ultrasound, allows the injection of the local anesthetic around the median, radial, ulnar and musculocutaneous nerves. The volume injected per nerve can vary from 5 to 8 ml depending on the visual appreciation during the injection.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Truncal ALR
Description: The anesthetic protocol in truncal block consists in injecting the local anesthetic around the median and ulnar nerves by a puncture performed at the elbow or forearm (depending on the practitioner's experience). The volumes injected remain the same and the puncture is also performed under ultrasound guidance. Additional local anesthesia is administered by injecting an additional 5 ml above the wrist flexion line to block the sensory territory of the musculocutaneous nerve.
Study: NCT02550002

Intervention type: DRUG
Intervention: Aflibercept
Description: Intravitreal injection

Intervention type: DRUG
Intervention: Aflibercept
Description: Intravitreal injection
Study: NCT03519984

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant EphB4-HSA Fusion Protein
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant EphB4-HSA Fusion Protein
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Liposomal
Description: Given IV
Study: NCT02078869

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone in oil
Description: Daily administration of 50 mg of IM Progesterone
Study: NCT02347436

Intervention type: PROCEDURE
Intervention: 24-hr ambulatory blood pressure measurement

Intervention type: PROCEDURE
Intervention: 24-hr ambulatory blood pressure measurement
Study: NCT03709758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax blocks an important pathway that promotes cell survival in tumor cells that overexpress BCL-2, so venetoclax causes cells to die
Study: NCT00963651

Intervention type: DEVICE
Intervention: Chest tomosynthesis and X-ray
Description: VolumeRAD tomosynthesis; Conventional Chest X-ray; Dual energy (bone and soft tissue PA chest images)
Study: NCT05712642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal Bevacizumab
Description: Serum systemic level of VEGF was measured before and after 1 week and 4 weeks of intravitreal injection of bevacizumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal Bevacizumab
Description: Serum systemic level of VEGF was measured before and after 1 week and 4 weeks of intravitreal injection of bevacizumab
Study: NCT02329119

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electrophysiological recordings

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: electrophysiological recordings
Study: NCT04549922

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ISIS 721744
Description: 1.2 mL of ISIS 721744 subcutaneous once after randomization

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 1.2 mL subcutaneous
Study: NCT01680783

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non invasive ventilation using a helmet hyperbaric device
Description: Patients randomized to the intervention group will receive noninvasive ventilation delivered via a latex-free helmet connected to the ventilator by conventional tubing.~If endotracheal intubation is required, the helmet will be removed and the patient will be intubated without delay.

Intervention type: OTHER
Group type: OTHER
Intervention: Noninvasive ventilation via facemask
Description: Patients assigned to the conventional ventilation group will continue noninvasive ventilation via facemask
Study: NCT02490306

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Strokefinder MD100 measurement
Description: A microwave measurement will be performed with the patient lying in the hospital bed or another suitable surface. Follow-up microwave measurements will be performed after the acute phase.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Strokefinder MD100 measurement
Description: A microwave measurement will be performed with the patient lying in the hospital bed or another suitable surface. Follow-up microwave measurements will be performed after the acute phase.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Strokefinder MD100 measurement
Description: A microwave measurement will be performed with the patient lying in the hospital bed or another suitable surface. Follow-up microwave measurements will be performed after the acute phase.
Study: NCT03445299

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music
Description: Listening to music for 30 minutes at bedtime
Study: NCT00606502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pralatrexate
Description: Intravenous (IV) push administration over 3-5 minutes into a patent IV line containing normal saline (0.9% sodium chloride).~Initial dose: 230 mg/m2, increased to 270 mg/m2 if patient does not have specific adverse events (AEs) as per the protocol after receipt of 2 consecutive doses 2 weeks apart. Reductions allowed in 40 mg/m2 decrements to 190 mg/m2 per the protocol defined dose modifications.~Protocol amended dose: 190 mg/m2, then 230 mg/m2 if patient does not have specific AEs per the protocol after receipt of 2 consecutive doses 2 weeks apart. Reductions allowed in 40 mg/2 decrements to 150 mg/m2 per the protocol defined dose modifications.~Administered on days 1 and 15 of a 4-week cycle (every 2 weeks) until criteria for discontinuation per the protocol are met.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erlotinib
Description: 150 mg orally in tablet form~Administered daily 1 hour before or 2 hours after ingestion of food until criteria for discontinuation per the protocol are met.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin B12
Description: 1 mg intramuscular injection~Administered within 10 weeks of randomization, every 8-10 weeks throughout the study and for at least 30 days after last dose of study treatment.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B12
Description: 1 mg intramuscular injection~Administered within 10 weeks of randomization, every 8-10 weeks throughout the study and for at least 30 days after last dose of study treatment.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Folic Acid
Description: 1-1.25 mg orally~Administered daily for at least 7 days prior to randomization, throughout the study and for at least 30 days after last dose of study treatment.
Study: NCT03709758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: Chemotherapy is most effective at killing cells that are rapidly dividing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Chemotherapy is most effective at killing cells that are rapidly dividing.
Study: NCT04496050

Intervention type: DRUG
Intervention: Prostaglandin E1
Description: The same drug will be used. In this study the same patients will be evaluated after the same dose of medication.
Study: NCT00622219

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Randomized Drug Testing Trial
Description: Adolescents in the experimental condition will receive all of the services offered by the Adolescent Substance Abuse Program (including individual meetings, parent and adolescent group meetings, psychopharmacology as indicated)and will be enrolled in a random drug testing program (with an average of 12 requests for testing over a 12 week period).
Study: NCT02078869

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vaginal progesterone suppositories
Description: Vaginal Promterium 200 mg , 3 times a day
Study: NCT00239083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enteric-Coated Mycophenolate Sodium (EC-MPS)
Study: NCT00724217

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Process 21 Day Purification Program (SPPP)
Description: The Standard Process 21 Day Purification Program (SPPP) consists of a controlled food intake regimen of mostly fruit and vegetables with restricted calories, protein and fats plus daily use of herbal and whole food based supplements.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Process 21 Day Purification Program (SPPP)
Description: The Standard Process 21 Day Purification Program (SPPP) consists of a controlled food intake regimen of mostly fruit and vegetables with restricted calories, protein and fats plus daily use of herbal and whole food based
Study: NCT00606502

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: 1-1.25 mg orally~Administered daily for at least 7 days prior to randomization, throughout the study and for at least 30 days after last dose of study treatment.
Study: NCT03354455

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation
Description: Frequency: 1 Hz., Pulse shape: biphasic, Duration: 30 minutes (1800 pulses).~Neuronavigation: MRI-guided and robot-assisted neuronavigation using Localite software and an Axilum robot.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Repetitive transcranial magnetic stimulation
Description: Frequency: 1 Hz., Pulse shape: biphasic, Duration: 30 minutes (1800 pulses).~Neuronavigation: MRI-guided and robot-assisted neuronavigation using Localite software and an Axilum robot.
Study: NCT01812135

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 400 U EV71 vaccine with adjuvant
Description: 400 U EV71 vaccine contain 0.4 mg AL/0.5 ml aluminum hydroxide adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 400 U EV71 vaccine with adjuvant
Description: 400 U EV71 vaccine contain 0.4 mg AL/0.5 ml aluminum hydroxide adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 400 U EV71 vaccine with adjuvant
Description: 400 U EV71 vaccine contain 0.4 mg AL/0.5 ml aluminum hydroxide adjuvant
Study: NCT02394691

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation
Description: anodal transcranial direct current stimulation on the left dorsolateral prefrontal cortex for the anodal session and sham stimulation (5secondes of tDCS) for the sham session

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: transcranial direct current stimulation
Description: anodal transcranial direct current stimulation on the left dorsolateral prefrontal cortex for the anodal session and sham stimulation (5secondes of tDCS) for the sham session